ライフサイエンスコーパス: natriuretic peptide

1 g/mL) serum NT-proBNP (N-terminal pro-B-type natriuretic peptide).

2 C-reactive protein and N-terminal pro B-type natriuretic peptide.

3 perative end-systolic volume index or B-type natriuretic peptide.

4 unoassay protocol for the detection of brain natriuretic peptide.

5 s, and higher levels of N-terminal pro-brain natriuretic peptide.

6 further adjustment for N-terminal pro-B-type natriuretic peptide.

7 natriuretic peptide or N-terminal pro-brain natriuretic peptide.

8 asive hemodynamics, and N-terminal pro-brain natriuretic peptide.

9 cture and function, and N-terminal pro brain natriuretic peptide.

10 itional markers, such as N-terminal probrain natriuretic peptide.

11 nt, peripheral ischemic preconditioning, and natriuretic peptide.

12 ft ventricular ejection fraction, and B-type natriuretic peptide.

13 osterone system and decreased sensitivity to natriuretic peptides.

14 is a membrane-bound enzyme that breaks down natriuretic peptides.

15 lower circulating levels of atrial and brain natriuretic peptides.

16 th resistance to diuretics and to endogenous natriuretic peptides.

17 g/m(2); P<0.0001) and a smaller reduction in natriuretic peptides.

18 oid hormone, prolactin, N-terminal pro-brain natriuretic peptide, 25-hydroxyvitamin D) and 2 nonhormo

19 nin T (0.05 ng/ml) and N-terminal pro-B-type natriuretic peptide (3,000 pg/ml).

20 f reduced survival were elevated serum brain natriuretic peptide (482 +/- 337 pg/mL) and uric acid (8

21 med BNP and LV-GLS were 4.04 (absolute brain natriuretic peptide: 60 pg/dL) and -20.7%.

22 ; P = 0.001), and serum N-terminal pro-brain natriuretic peptide (647 +/- 1,127 pg/ml vs. 1,578 +/- 2

23 e and soluble epoxide hydrolase, agonists of natriuretic peptide A and vasoactive intestinal peptide

24 "super"-induction of fetal genes, including natriuretic peptides A and B (Nppa/Nppb).

25 C-type natriuretic peptide activation of guanylyl cyclase B (GC

26 centric left ventricular remodeling, greater natriuretic peptide activation, higher filling pressures

27 justed for age, sex, and N-terminal probrain natriuretic peptide: adrenomedullin (hazard ratio per lo

28 -pro-arginine vasopressin, and MR-pro-atrial natriuretic peptide), alone or as a panel, could be usef

29 More recent evidence suggests that natriuretic peptides along with the next generation of b

30 dest improvement over a model without B-type natriuretic peptide and ankle-brachial index (C statisti

31 s had echocardiograms and measures of B-type natriuretic peptide and C-reactive protein before the pr

32 V mass and DeltaLV mass, N-terminal probrain natriuretic peptide and change in N-terminal probrain na

33 signaling by extracellular peptides (C-type natriuretic peptide and EGF receptor ligands) maintain t

34 Circulating N-terminal pro-B-type natriuretic peptide and high-sensitivity cardiac troponi

35 sma concentrations of N- terminal pro-B-type natriuretic peptide and high-sensitivity cardiac troponi

36 age, biomarkers (N-terminal fragment B-type natriuretic peptide and high-sensitivity cardiac troponi

37 obustly associated with N-terminal pro-brain natriuretic peptide and incident HF or death.

38 on who underwent mitral valve surgery, brain natriuretic peptide and LV-GLS provided synergistic risk

39 To further investigate the local action of natriuretic peptide and p38 MAPK in podocytes, we genera

40 size) with concomitant N-terminal pro-brain natriuretic peptide and subsequent HF hospitalization or

41 Elevated brain natriuretic peptide and uric acid, decreased left ventri

42 Changes in insulin signaling, circulating natriuretic peptides and adipokines, and varied expressi

43 nzyme responsible for the degradation of the natriuretic peptides and many other vasoactive peptides.

44 d potential mediators, including BNP (B-type natriuretic peptide) and endothelin-1.

45 natriuretic peptides (N-terminal pro-B type natriuretic peptide) and rest/exercise echocardiography

46 in primary (change in N-terminal pro B-type natriuretic peptide) and secondary (change in left atria

47 ination of standard CVD risk factors, B-type natriuretic peptide, and ankle-brachial index (model 6)

48 aditional risk factors, N-terminal pro-brain natriuretic peptide, and baseline hs-cTnT level.

49 ic peptide and change in N-terminal probrain natriuretic peptide, and body mass index (P<0.05 for eac

50 entrations of glucose, N-terminal pro-B type natriuretic peptide, and cystatin C.

51 on cardiac troponin I, N-terminal pro-B-type natriuretic peptide, and d-dimer levels at baseline.

52 Cardiac troponin I, N-terminal pro-B-type natriuretic peptide, and d-dimer levels were measured at

53 e measured (troponin T, N-terminal pro-brain natriuretic peptide, and heart-type fatty acid binding p

54 ejection fraction with N-terminal pro-brain natriuretic peptide, and high-sensitive troponin was neg

55 ensitivity troponin T, N-terminal pro-B-type natriuretic peptide, and high-sensitivity C-reactive pro

56 n, D-dimer, troponin T, N-terminal pro-brain natriuretic peptide, and high-sensitivity C-reactive pro

57 iltration rate, higher N-terminal pro-B-type natriuretic peptide, and ischemic cause of heart failure

58 iotensin inhibition therapy, elevated B-type natriuretic peptide, and larger left ventricular end-dia

59 mer, homoarginine, and N-terminal pro B-type natriuretic peptide, and lower levels of low-density lip

60 chronic kidney disease, N-terminal-pro brain natriuretic peptide, and lymphocyte GRK2 protein levels

61 class or Ross class), N-terminal pro-B-type natriuretic peptide, and quality of life (QOL) were asse

62 ometry, measurement of N-terminal pro-B-type natriuretic peptide, and subjective health assessment.

63 duced fat oxidation to affect cardiac atrial natriuretic peptide, and thus, induce adipose lipolysis,

64 pericardial effusion, N-terminal pro-B-type natriuretic peptide, and troponin T.

65 ed for known predictors, including age, sex, natriuretic peptides, and comorbidity.

66 ns with abnormal cardiac structure/function, natriuretic peptides, and incident heart failure (HF) is

67 ly used plasma biomarkers include troponins, natriuretic peptides, and lipoprotein particles, yet int

68 vity troponin and N-terminal fragment B-type natriuretic peptide], and clinical history of prior stro

69 troponins, NT-proBNP [N-terminal pro-B-type natriuretic peptide], and galectin-3).

70 e cardiac natriuretic peptides (NPs), atrial natriuretic peptide (ANP) and B-type natriuretic peptide

71 1-regulated cardioprotective peptides atrial natriuretic peptide (ANP) and B-type natriuretic peptide

72 Cardiomyocytes secrete atrial natriuretic peptide (ANP) and B-type natriuretic peptide

73 Atrial natriuretic peptide (ANP) has a central role in regulati

74 Atrial natriuretic peptide (ANP) influences glucose homeostasis

75 Atrial natriuretic peptide (ANP) is a hormone with numerous ben

76 The natriuretic peptides are biochemical markers of heart fa

77 importance of NEP inhibition for augmenting natriuretic peptides as a therapeutic target.

78 de concentrations and compared the impact of natriuretic peptide-associated genetic variants on blood

79 of soluble ST2 and amino-terminal pro-B-type natriuretic peptide at 12 hours added value to CardShock

80 N-terminal pro B-type natriuretic peptide (available in 2632 patients) was als

81 mRNA expression of the cardiac stress marker natriuretic peptide B is also observed in the right vent

82 mRNA expression of myosin heavy chain 7 and natriuretic peptide B is up-regulated in both ventricles

83 etic peptides, such as N-terminal pro-B-type natriuretic peptide/B-type natriuretic peptide, the 6-mi

84 ng, a 6-minute walk test, and measurement of natriuretic peptides before and 1 year after AVR.

85 Multivariable regression revealed that brain natriuretic peptide (beta=-0.250; P<0.001) and receptor

86 e determined whether plasma levels of B-type natriuretic peptide (BNP) and cardiac troponin I are ass

87 of activated T cells -c3 (NFATc3), and brain natriuretic peptide (BNP) compared to controls.

88 atrial natriuretic peptide (ANP) and B-type natriuretic peptide (BNP) in heart tissue may also contr

89 atrial natriuretic peptide (ANP) and B-type natriuretic peptide (BNP) in response to mechanical stre

90 B-type natriuretic peptide (BNP) is a guanylyl cyclase A (GC-A)

91 ous experimental studies suggest that B-type natriuretic peptide (BNP) is cardioprotective; however,

92 at risk" for HFpEF given elevated brain-type natriuretic peptide (BNP) level; 160 had HFpEF by docume

93 Studies suggesting that B-type natriuretic peptide (BNP) may predict outcomes of mitral

94 Brain natriuretic peptide (BNP) serum concentration has been s

95 odium calcium exchanger (Ncx1) and the brain natriuretic peptide (Bnp) whose hypertrophic upregulatio

96 Circulating RBP4, TTR, B-type natriuretic peptide (BNP), and troponin I (TnI) concentr

97 atrial natriuretic peptide (ANP) and B-type natriuretic peptide (BNP), have central roles in sodium

98 We have reported that pro-B-type natriuretic peptide (BNP)-1-108 circulates and is proces

99 eft ventricular ejection fraction and b-type natriuretic peptide (BNP).

100 iber direction increased expression of brain natriuretic peptide, but off-axis stretches (causing fib

101 d blocking angiotensin II signaling, augment natriuretic peptides by inhibiting their breakdown by ne

102 rtality in addition to N-terminal pro-B-type natriuretic peptide (C-statistic: 0.59 versus 0.63) and

103 reatine kinase, myoglobin, N-terminal B-type natriuretic peptide, C-reactive protein, and leukocyte c

104 e still learning how complex the dynamics of natriuretic peptides can be in the interpretation of tes

105 ulated cardiomyocyte contractility by atrial natriuretic peptide/cGMP signaling in early cardiac hype

106 ood samples were evaluated for cardiac brain natriuretic peptide, choline, and TMAO levels.

107 ivating mutations in the receptor for C-type natriuretic peptide (CNP), guanylyl cyclase B (GC-B, als

108 andidate therapy employs an analog of C-type natriuretic peptide (CNP), which antagonizes the mitogen

109 r expression of cardiac stress genes (B-type natriuretic peptide, collagen gene expression), less car

110 sus 40), higher median N-terminal pro-B-type natriuretic peptide concentration (403 versus 320 pg/mL;

111 o -0.8, p=0.0070), and N-terminal pro B-type natriuretic peptide concentration in plasma -970 pg/mL (

112 se without LVSD, plasma N-terminal pro-brain natriuretic peptide concentration was greater than 400 p

113 me, including central venous pressure, brain-natriuretic-peptide concentration, and fractional urinar

114 ciated with NT-proBNP (N-terminal pro-B-type natriuretic peptide) concentration (0.57 on a log scale

115 e effects of genetic variants on circulating natriuretic peptide concentrations and compared the impa

116 extensive adjustments, N-terminal pro-B-type natriuretic peptide concentrations predicted ICU or 90-d

117 PDEs controlling natriuretic-peptide-coupled cGMP remain uncertain.

118 r molecule that transduces nitric-oxide- and natriuretic-peptide-coupled signalling, stimulating phos

119 Short-term mechanical circulatory support, natriuretic peptide decile, glomerular filtration rate,

120 Plasma concentrations of natriuretic peptides decline with obesity in patients wi

121 urin measurements, and N-terminal pro-B-type natriuretic peptide did not improve patient classificati

122 isease as indicated by N-terminal pro B-type natriuretic peptide, E/E', and left atrial volume.

123 in mice revealed that this unexpected atrial natriuretic peptide effect is brought about by spatial r

124 er adjustment for age, N-terminal pro-B-type natriuretic peptide, ejection fraction, E/E', and left v

125 nt after adjustment for N-terminal pro-brain natriuretic peptide, ejection fraction, stroke volume in

126 Increasing evidence behind the use of natriuretic peptides, emergence of novel biomarkers, and

127 Only 4 drugs (brain natriuretic peptide, exenatide, metoprolol, and esmolol)

128 These results indicate that natriuretic peptide exerts a renoprotective effect via i

129 rotein kinase IIdelta phosphorylation, brain natriuretic peptide expression, and sustained capillariz

130 stolic dysfunction and had higher myocardial natriuretic peptide expression.

131 e 2 began with de Bold's discovery of atrial natriuretic peptide, followed by isolation of the enzyme

132 in exercise capacity, functional class, and natriuretic peptides from baseline to 12 months, but tre

133 Exercise testing, echocardiography, B-type natriuretic peptide, functional health assessment, and m

134 >/= 500 ng/mL and amino-terminal pro-B-type natriuretic peptide, >/= 4,500 ng/L) had higher 30-day m

135 The concept of natriuretic peptide guidance has been extensively studie

136 The effect of NT-proBNP (N-terminal probrain natriuretic peptide)-guided therapy in patients with acu

137 r, cardiac expression of peptides other than natriuretic peptides has only been suggested using trans

138 BACKGROUND AND Natriuretic peptides have led the way as a diagnostic an

139 left atrium dimension, E/e', and pro B-type natriuretic peptide (hazard ratio, 1.05; 95% confidence

140 p = 0.040), as well as N-terminal pro-brain natriuretic peptide (hazard ratio: 1.655; p < 0.001) and

141 tional class [WHO-FC], N-terminal-pro-B-type natriuretic peptide, hemodynamics) and lung-transplantat

142 ronary artery calcium, N-terminal pro B-type natriuretic peptide, high-sensitivity cardiac troponin T

143 Levels of N-terminal fragment B-type natriuretic peptide, high-sensitivity cardiac troponin T

144 ronary artery calcium, N-terminal pro B-type natriuretic peptide, high-sensitivity cardiac troponin T

145 to LCZ696 for lowering N-terminal pro B-type natriuretic peptide; however, left atrial volume reducti

146 Plasma levels of B-type natriuretic peptide, hs-TnI (high-sensitivity troponin I

147 When including B-type natriuretic peptide in the model, only a decreasing myoc

148 55 +/- 10%; p < 0.001; n = 259), and B-type natriuretic peptide increased (median [interquartile ran

149 In HF-CON, n-terminal pro-brain natriuretic peptide increased by 88 +/- 120 pg/mL during

150 Finally, we revealed that atrial natriuretic peptide increased phosphorylation of MAPK ph

151 Importantly, proBNP (pro-brain natriuretic peptide) increased at 12 months in 20 millio

152 oss, reduction in amino terminal, pro B-type natriuretic peptide, increased plasma renin activity, an

153 dysfunction and higher N-terminal pro brain natriuretic peptide independent of RA size and pressure.

154 CNP (C-type natriuretic peptide) inhibits myofibrogenesis and osteog

155 x metalloproteinase-3, N-terminal pro-B-type natriuretic peptide, interleukin-6, soluble CD40 ligand,

156 x metalloproteinase-3, N-terminal pro-B-type natriuretic peptide, interleukin-6, soluble CD40 ligand,

157 proportional change in N-terminal pro-B-type natriuretic peptide level from baseline to 180 days.

158 ), a 10-year risk of CVD < 20%, and a B-type natriuretic peptide level greater than their gender-spec

159 [IQR, 19%-33%]; median N-terminal pro-B-type natriuretic peptide level of 2049 pg/mL [IQR, 1054-4235

160 blem list, inpatient loop diuretic, or brain natriuretic peptide level of 500 pg/mL or higher; (3) lo

161 igns and symptoms of congestion and elevated natriuretic peptide level requiring hospitalization or o

162 iastolic diameter; serum troponin level; and natriuretic peptide level) in each individual.

163 e HR for a 1-SD higher N-terminal pro-B-type natriuretic peptide level, 1.15; 95% CI, 1.04-1.26), int

164 troponin T level, log N-terminal pro-B-type natriuretic peptide level, fibroblast growth factor 23 l

165 Age, B-type natriuretic peptide level, renal dysfunction, 24-h AHI,

166 apy but fewer comorbidities and lower B-type natriuretic peptide level.

167 have evaluated adjusting HF therapy based on natriuretic peptide levels ("guided therapy") with incon

168 55-2.44), and abnormal N-terminal pro-B-type natriuretic peptide levels (defined as >400 pg/mL; odds

169 e rates in addition to an increase in B-type natriuretic peptide levels (P=0.01), C-reactive protein

170 N-terminal pro-B-type natriuretic peptide levels decreased similarly in both g

171 N-terminal prohormone brain natriuretic peptide levels did not increase significantl

172 B-type natriuretic peptide levels increased over time and corre

173 roBNP levels of 1000 pg/mL or more or B-type natriuretic peptide levels of 250 pg/mL or more, regardl

174 Brain natriuretic peptide levels on admission were lower (medi

175 ctions from baseline in N-terminal pro-brain natriuretic peptide levels than did the pooled-monothera

176 N-terminal pro-B-type natriuretic peptide levels were abnormal in 97.4% of the

177 N-Terminal pro-B type natriuretic peptide levels were below the level consider

178 aride binding protein, troponin T, and brain natriuretic peptide levels were measured.

179 In contrast, N-terminal pro-B-type natriuretic peptide levels were not associated with mort

180 h HFrEF (ejection fraction </=40%), elevated natriuretic peptide levels within the prior 30 days, and

181 uality of life, higher N-terminal pro-B-type natriuretic peptide levels, and a poorer prognosis.

182 nd right ventricular structure and function, natriuretic peptide levels, and incident HF.

183 In Cox Proportional Hazard analyses, B-type natriuretic peptide levels, C-reactive protein levels, a

184 ity of life, incidence of arrhythmias, brain natriuretic peptide levels, left ventricular ejection fr

185 lation and diuretic use, n-terminal probrain natriuretic peptide levels, renal dysfunction, neurohumo

186 0.0001), despite lower N-terminal pro-B-type natriuretic peptide levels.

187 d significantly higher N-terminal pro-B-type natriuretic peptide levels; in addition, early rise in N

188 ceptors and NT-proBNP (N-Terminal Pro-B-Type Natriuretic Peptide) levels were important across all ou

189 lthough LCZ696 reduced N-terminal pro B-type natriuretic peptide, levels of the other 4 biomarkers we

190 ysteine <10 micromol/L, N-terminal pro-brain natriuretic peptide <100 pg/mL, no microalbuminuria, no

191 3, NAC+NaHCO3, ischemic preconditioning, and natriuretic peptide may have nephroprotective effects, t

192 cardiography and plasma N-terminal pro-brain natriuretic peptide measurement and were followed for up

193 Although natriuretic peptide measurements are widely used in prac

194 Circulating natriuretic peptide measurements have been used extensiv

195 Natriuretic peptide measurements have clearly revolution

196 Interpretation of natriuretic peptide measurements will depend on many fac

197 he reduced fat oxidation and elevated atrial natriuretic peptide message of cardiac hypertrophy.

198 rular filtration rate, N-terminal pro-B-type natriuretic peptide, mineralocorticoid receptor antagoni

199 g as that obtained for N-terminal pro-B-type natriuretic peptide (multivariable HR for a 1-SD higher

200 Current guidelines recommend use of natriuretic peptides (N-terminal pro-B type natriuretic

201 s the increased cardiac expression of atrial natriuretic peptide (NP) and B-type NP, with their plasm

202 ion between the renal sympathetic nerves and natriuretic peptide (NP) metabolism.

203 e association between achieving predischarge natriuretic peptide (NP) thresholds and mortality and re

204 e association between achieving predischarge natriuretic peptide (NP) thresholds and mortality and re

205 Natriuretic peptides (NP) have prognostic value in heart

206 tify musclin-a peptide with high homology to natriuretic peptides (NP)-as an exercise-responsive myok

207 Biologically active natriuretic peptides (NPs) are an integral part of cardi

208 The cardiac natriuretic peptides (NPs), atrial natriuretic peptide (

209 The cardiac natriuretic peptides (NPs), atrial NP and B-type NP, reg

210 The functional homologues of vertebrate natriuretic peptides (NPs), the plant natriuretic peptid

211 )-A, also known as NPR-A or NPR1, by cardiac natriuretic peptides (NPs).

212 determinants of plasma N-terminal proatrial natriuretic peptide (NT-proANP) in the general community

213 N-terminal pro-brain natriuretic peptide (NT-proBNP) and high-sensitivity car

214 ether the N-terminal of the prohormone brain natriuretic peptide (NT-proBNP) and high-sensitivity tro

215 Hokusai-VTE study used N-terminal pro-brain natriuretic peptide (NT-proBNP) and right to left ventri

216 Combining abnormal N-terminal pro-brain natriuretic peptide (NT-proBNP) and troponin T with live

217 Increased N-terminal pro-B-type natriuretic peptide (NT-proBNP) concentration predicts p

218 N-terminal pro-B-type natriuretic peptide (NT-proBNP) is a strong predictor of

219 whether a reduction in N-terminal pro-B-type natriuretic peptide (NT-proBNP) is associated with impro

220 Serum N-terminal pro-B-type natriuretic peptide (NT-proBNP) is considered a marker t

221 .001); and had higher N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels (P < .001), large

222 tone and usual care on N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels compared with usu

223 ST2 and N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels were measured in

224 walk distance, plasma N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels, and health statu

225 patients with elevated N-terminal pro-brain natriuretic peptide (NT-proBNP) levels, reduces the inci

226 s associated with lower N-terminal pro-brain natriuretic peptide (NT-proBNP) levels.

227 n those with available N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels.

228 troponin T (hsTnT) and N-terminal pro-B-type natriuretic peptide (NT-proBNP) strongly predict heart f

229 kers (such as N-terminal prohormone of brain natriuretic peptide (NT-proBNP)) and a measure of functi

230 ied the association of N-terminal pro-B-type natriuretic peptide (NT-proBNP), high-sensitive troponin

231 ortant biomarkers were N-terminal pro-B-type natriuretic peptide (NT-proBNP), high-sensitivity cardia

232 ercent change in serum N-terminal pro-B-type natriuretic peptide (NT-proBNP), high-sensitivity tropon

233 ether repeated measurements of NT-pro-B-type natriuretic peptide (NT-proBNP), troponin T (TropT) and

234 he association between N-terminal pro-B-type natriuretic peptide (NT-proBNP), which is a marker of he

235 termine whether an amino-terminal pro-B-type natriuretic peptide (NT-proBNP)-guided treatment strateg

236 distance, and levels of N-terminal pro-brain natriuretic peptide (NT-proBNP).

237 g-transformed level of N-terminal pro-B-type natriuretic peptide (NT-proBNP).

238 tional class, N-terminal prohormone of brain natriuretic peptide (NT-proBNP)concentrations, Borg dysp

239 +/- 0.04, P = .01) and N-terminal pro-brain natriuretic peptide (NT-proBNP; 191 +/- 261 vs 33 +/- 33

240 tance [6MWD], N-terminal prohormone of brain natriuretic peptide [NT-proBNP] concentration, and WHO f

241 nins I and T, N-terminal prohormone of brain natriuretic peptide [NT-proBNP]) to predict baseline sus

242 (that is stage III with N-terminal pro-brain natriuretic peptide [NTproBNP] >8500 pg/mL) disease, VWF

243 n of nitric oxide-CAPON signalling and brain natriuretic peptide on cGMP and cAMP regulation of cardi

244 Y708C, R776W, and G959A) bound (125)I-C-type natriuretic peptide on the surface of cells but failed t

245 Early changes in N-terminal pro-B-type natriuretic peptide or high-sensitivity cardiac troponin

246 , and an elevated circulating level of brain natriuretic peptide or N-terminal pro-brain natriuretic

247 LA volume, NT-proBNP (N-terminal pro-B-type natriuretic peptide), or left ventricular E/e' (all P<0.

248 mass index (p = 0.002), N-terminal pro-brain natriuretic peptide (p < 0.001), early mitral inflow vel

249 nd had higher levels of N-terminal pro-brain natriuretic peptide (p = 0.001) compared with less sympt

250 exercise capacity, and N-terminal pro-brain natriuretic peptide (P>0.30 for all).

251 rrelated with N-terminal prohormone of brain natriuretic peptide (P<0.001), 6-minute walk distance (P

252 stance, and NT-proBNP (N-terminal pro-B-type natriuretic peptide; P<0.05 for all).

253 egulating liver X receptor alpha through the natriuretic peptide pathway.

254 ebrate natriuretic peptides (NPs), the plant natriuretic peptides (PNPs), are a novel class of peptid

255 tension, and corin activation and pro-atrial natriuretic peptide processing activity were undetectabl

256 lobal longitudinal strain (LV-GLS) and brain natriuretic peptide provided incremental prognostic util

257 or soluble ST2 and amino-terminal pro-B-type natriuretic peptide provides early risk assessment beyon

258 r myeloperoxidase (r=0.42, P<0.0001), B-type natriuretic peptide (r=0.25, P=0.001), and asymmetrical

259 ferentiation via the guanylate cyclase NPR2 (natriuretic peptide receptor 2) and not the G-protein-co

260 e G-protein-coupled clearance receptor NPR3 (natriuretic peptide receptor 3).

261 ing at a low concentration by binding to its natriuretic peptide receptor A (NPRA) receptor and, in t

262 membrane guanylyl cyclase 1 (RetGC1) but not natriuretic peptide receptor A (NPRA).

263 The intracellular segment of a natriuretic peptide receptor A guanylyl cyclase failed t

264 of guanylyl cyclase B (GC-B), also known as natriuretic peptide receptor B or NPR2, stimulates long

265 ecorded in atrial myocytes from wild-type or natriuretic peptide receptor C knockout (NPR-C(-/-)) mic

266 The ratio of the signaling receptor, natriuretic peptide receptor type A, to the clearance re

267 Guanylyl cyclase-A (GC-A) signaling, a natriuretic peptide receptor, exerts renoprotective effe

268 rdiomyocyte death, and N-terminal pro B-type natriuretic peptide release; all are classical hallmarks

269 The atrial natriuretic peptide secreted by atrial myocytes is a maj

270 of soluble ST2 and amino-terminal pro-B-type natriuretic peptide showed excellent discrimination for

271 encodes an enzyme that degrades circulating natriuretic peptides, showed the strongest differential

272 trast to well-documented beta-adrenergic and natriuretic peptide signaling desensitization during chr

273 Increased activation of natriuretic peptide signaling was seen in white AT of HF

274 kinase-1alpha (PKG1alpha) transduces NO and natriuretic peptide signaling; therefore, PKG1alpha acti

275 These include natriuretic peptides, soluble suppressor of tumorgenicit

276 rt the use of 3 such intermediate endpoints: natriuretic peptides, such as N-terminal pro-B-type natr

277 dy), high-sensitivity troponin I, and B-type natriuretic peptide ( Table 1 ).

278 tatin C, syndecan-4, and N terminal-probrain natriuretic peptide than HF patients (all p </= 0.01).

279 essure and in levels of N-terminal pro-brain natriuretic peptide than the placebo group.

280 g levels of NT-proBNP (N-terminal pro-B-type natriuretic peptide) than HF patients without AF.

281 echocardiographic parameters and circulating natriuretic peptides that confound HFpEF diagnosis.

282 rminal pro-B-type natriuretic peptide/B-type natriuretic peptide, the 6-min walk test distance, and h

283 orin is a serine protease that activates the natriuretic peptides, thereby regulating blood pressure.

284 circulating NT-proBNP (N-terminal pro-B-type natriuretic peptide), TNF-alpha, IL-6, IL-12, IL-17, mal

285 of soluble ST2 and amino-terminal pro-B-type natriuretic peptide to clinical parameters for risk stra

286 trial volume, N-terminal propeptide of brain natriuretic peptide, total, collagen-dependent, and titi

287 ection fraction, plasma n-terminal pro-brain natriuretic peptide, tumor necrosis factor-alpha, and C-

288 e found between any 2 time points for B-type natriuretic peptide, tumor necrosis factor-alpha, IL-1b,

289 ft ventricles revealed three specific genes [natriuretic peptide type A (Nppa), sarcolipin (Sln), and

290 rdiac stage III patients (amino-terminal pro-natriuretic peptide type B >8500 ng/L) had lower respons

291 volumes, scar size, and N-terminal pro-brain natriuretic peptide values comparing the 2 treatment gro

292 ntricular ejection fraction, and lower brain natriuretic peptide values on admission.

293 Elevated N-terminal pro-B-type natriuretic peptide was also associated with an increase

294 ddition, early rise in N-terminal pro-B-type natriuretic peptide was associated with a better outcome

295 -week-old animals, and the PCH marker atrial natriuretic peptide was not different in young versus ol

296 Median levels of brain natriuretic peptide were 550 pg/mL in patients with a BM

297 nction, end-systolic volume index and B-type natriuretic peptide were most strongly associated with S

298 itivity troponin T and midregional proatrial natriuretic peptide were prospectively analyzed in 109 p

299 spnea, and elevated plasma concentrations of natriuretic peptides were randomized to receive a double

300 RI, and log NT-proBNP (N-Terminal Pro-B-Type Natriuretic Peptide) were retained (chi(2), 62.2; P<0.00